BioAlliance commences Phase II trial of oral mucositis candidate Validive

BioAlliance Pharma has commenced a Phase II clinical trial of Validive (clonidine Lauriad) to assess the its efficacy and safety profile in treating chemoradiation therapy-induced oral mucositis in head and neck cancer patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news